We are live on
!
Find out more
BB
BB Biotech Portfolio holdings
AUM
$3.98B
1-Year Est. Return
15.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.05%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$2.53B
AUM Growth
+$17.2M
(+0.68%)
Cap. Flow
+$30.8M
Cap. Flow
% of AUM
1.22%
Top 10 Holdings %
Top 10 Hldgs %
72.66%
Holding
32
New
3
Increased
6
Reduced
2
Closed
2
Avg Time Held
7.5
quarters
Top 10 Avg Time Held
9.4
quarters
Top 20 Avg Time Held
8.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intra-Cellular Therapies Inc.
ITCI
|
+$25.2M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$20.6M |
| 3 |
MacroGenics
MGNX
|
+$11.7M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$10.5M |
| 5 |
Agios Pharmaceuticals
AGIO
|
+$10M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$33.5M |
| 2 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
+$14.2M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$10.1M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$3.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.26% |
| 2 | Miscellaneous | 4.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $356M | 14.05% |
3,609,298
| – | – |
2013 Q2
12 quarters
|
|
2
Incyte
INCY
$22.9B
| $307M | 12.12% |
3,840,406
| – | – |
2013 Q2
12 quarters
|
|
3
Gilead Sciences
GILD
$187B
| $231M | 9.14% |
2,774,596
| – | – |
2013 Q2
12 quarters
|
|
|
4
Ionis Pharmaceuticals
IONS
$7.52B
| $165M | 6.53% |
7,104,838
+325,000
| +5% | +$10.5M |
2013 Q2
12 quarters
|
|
5
DELISTED
Radius Health, Inc.
RDUS
| $160M | 6.33% |
4,360,399
| – | – |
2014 Q2
8 quarters
|
|
6
Neurocrine Biosciences
NBIX
$14.5B
| $142M | 5.6% |
3,121,552
| – | – |
2013 Q3
11 quarters
|
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
| $138M | 5.44% |
1,179,428
+145,000
| +14% | +$20.6M |
2013 Q2
12 quarters
|
|
8
Vertex Pharmaceuticals
VRTX
$129B
| $122M | 4.81% |
1,415,445
+50,000
| +4% | +$4.32M |
2013 Q2
12 quarters
|
|
|
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
| $120M | 4.74% |
1,991,112
-590,000
| -23% | -$33.5M |
2013 Q2
12 quarters
|
|
|
10
Agios Pharmaceuticals
AGIO
$1.9B
| $99M | 3.91% |
2,363,321
+203,400
| +9% | +$10M |
2014 Q2
8 quarters
|
|
|
TSRO
11
DELISTED
TESARO, Inc.
TSRO
| $97M | 3.83% |
1,154,582
-75,000
| -6% | -$3.34M |
2013 Q3
11 quarters
|
|
12
Regeneron Pharmaceuticals
REGN
$76.9B
| $71.6M | 2.83% |
205,000
| – | – |
2013 Q3
11 quarters
|
|
13
Alnylam Pharmaceuticals
ALNY
$31.1B
| $66.1M | 2.61% |
1,191,338
| – | – |
2013 Q2
12 quarters
|
|
14
Halozyme
HALO
$12.5B
| $63.7M | 2.51% |
7,379,832
| – | – |
2013 Q2
12 quarters
|
|
15
Novavax
NVAX
$2.1B
| $60.6M | 2.39% |
416,500
| – | – |
2014 Q3
7 quarters
|
|
|
JUNO
16
DELISTED
Juno Therapeutics, Inc.
JUNO
| $50.2M | 1.98% |
1,305,000
| – | – |
2015 Q2
4 quarters
|
|
|
ALDR
17
DELISTED
Alder Biopharmaceuticals
ALDR
| $42.1M | 1.66% |
1,685,150
+175,000
| +12% | +$4.73M |
2015 Q2
4 quarters
|
|
|
KITE
18
DELISTED
Kite Pharma, Inc.
KITE
| $37.5M | 1.48% |
750,000
| – | – |
2015 Q2
4 quarters
|
|
|
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $36.5M | 1.44% |
255,719
| – | – |
2015 Q1
5 quarters
|
|
|
CEMP
20
DELISTED
Cempra, Inc.
CEMP
| $33.7M | 1.33% |
2,041,900
| – | – |
2014 Q4
6 quarters
|
|
|
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $27.2M | 1.07% |
+700,000
| New | +$25.2M |
2016 Q2
0 quarters
|
|
22
DELISTED
Sage Therapeutics
SAGE
| $25.6M | 1.01% |
850,639
+16,976
| +2% | +$566K |
2015 Q4
2 quarters
|
|
|
23
MacroGenics
MGNX
$238M
| $14M | 0.55% |
+520,000
| New | +$11.7M |
2016 Q2
0 quarters
|
|
24
Puma Biotechnology
PBYI
$531M
| $12.9M | 0.51% |
431,991
| – | – |
2014 Q1
9 quarters
|
|
25
Prothena Corp
PRTA
$454M
| $12.2M | 0.48% |
350,000
| – | – |
2015 Q3
3 quarters
|
|
Similar funds
SBAM
HFS
SA
WF
BCPEM
DCM
AB
MFBTD
BB Biotech's Q2 2016 Portfolio in Review
As of Q2 2016, BB Biotech held 32 positions worth $2.53B, up 0.68% from $2.52B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
BB Biotech's Q2 2016 filing shows 3 new, 6 increased, 2 reduced and 2 closed positions. Its largest new stake was Intra-Cellular Therapies Inc.: 700,000 shares worth $27.2M. The largest sale was MEDIVATION, INC., an estimated $33.5M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Miscellaneous.
- BB Biotech's largest Q2 2016 buy was Intra-Cellular Therapies Inc.: 700,000 shares worth $27.2M.
- BB Biotech added most to Alexion Pharmaceuticals in Q2 2016, an estimated $20.6M increase.
- BB Biotech's biggest Q2 2016 reduction was MEDIVATION, INC., cutting an estimated $33.5M.
- BB Biotech fully exited Infinity Pharmaceuticals, Inc. in Q2 2016, selling an estimated $14.2M.
- BB Biotech's ten largest holdings make up 73% of its $2.53B portfolio in Q2 2016.
- BB Biotech opened 3 new positions and closed 2 in Q2 2016.
- BB Biotech's portfolio value rose 0.68% quarter-over-quarter to $2.53B.
Based on BB Biotech's 13F filing for Q2 2016, filed 12 Aug 2016.